Clinical profile and therapeutic strategies in patients with arrhythmogenic cardiomyopathy treated in a national reference institute
DOI:
https://doi.org/10.47487/apcyccv.v2i1.123Keywords:
Ventricular tachycardia, sudden cardiac death, Arrhytmogenic right ventricular dysplasiaAbstract
Objective. To determine the epidemiological, clinical, electrocardiographic, imaging characteristics and main therapeutic strategies performed in patients with arrhythmogenic cardiomyopathy treated in a national reference cardiovascular institute.
Materials and methods. Observational, descriptive and retrospective study that attempts to identify the clinical characteristics, complementary tests and therapeutic strategies performed in patients with arrhythmogenic cardiomyopathy treated at the National Cardiovascular Institute - INCOR EsSalud in Lima, Peru.
Results. Thirteen patients were found with arrhythmogenic cardiomyopathy. The median age at which the diagnosis was made was 38.2 years and 69.3% of those affected were male. The most frequent clinical manifestations were tachycardic palpitations (92.3%), presyncope (84.6%) and heart failure (69.2%). 23% of the patients suffered a cardiac arrest. All the patients presented at least one episode of ventricular tachycardia, 92.3% with complete left bundle branch block morphology and upper axis. 76.9% received an implantable cardioverter defibrillator (ICD), 15.3% underwent ablation and 15.3% received a heart transplant. 84.6% of the patients live to this day.
Conclusions. Arrhythmogenic cardiomyopathy predominantly affected the young and male population. All the patients had a potentially fatal ventricular arrhythmia. Biventricular disease by echocardiography and cardiac magnetic resonance occurred in 69.2% and 100% of the cases, respectively. The therapeutic strategies used were antiarrhythmic medical treatment, placement of an ICD as secondary prevention, ablation, and heart transplantation. To date, 84.6% of patients survive.
Downloads
References
Gandjbakhch E, Redheuil A, Pousset F. et al. Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Journal of the American college of cardiology 2018;72(7):784–804. DOI: https://doi.org/10.1016/j.jacc.2018.05.065
Cox M, Zwaag P, Van der W. et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy clinical perspective: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/ cardiomyopathy genotype-phenotype follow-up study. Circulation 2011; 123:2690–700. DOI: 10.1161/CIRCULATIONAHA.110.988287
Calkins H. Arrhythmogenic right ventricular dysplasia/cardiomyopathy-three decades of progress. Circulation Journal. 2015;79(12): 901–13. DOI-. 10.1253/circj.CJ-15-0288
Li K, Bazoukis G, Liu T et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in clinical practice. Journal of Arrhythmia. 2018; 34:11–22. DOI: 10.1002/joa3.12021
Weijia Wang C, Calkins H. Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient. Europace (2019) 21, 9–21. DOI: 10.1093/europace/euy063
Corrado D, Link M, Calkins H. Arrhythmogenic Right Ventricular Cardiomyopathy. N Engl J Med 2017; 376:61-72. DOI: 10.1056/NEJMra1509267
Gupta R, Tichnell C, Murray B, Rizzo S, Riele AT, Tandri H, et al. Comparison of features of fatal versus nonfatal cardiac arrest in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2017;120:111–7. DOI: 10.1016/j.amjcard.2017.03.251
Te Riele AS, James CA, Philips B. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol 2013;24:1311–1320. DOI: 10.1111/jce.12222
Riele T, Bhonsale A, James C, Rastegar N, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:1761–9. DOI: 10.1016/j.jacc.2012.11.087
Abrams D, Kirkby C, Page S, et al. Evolution of electrocardiographic and structural features over 3 decades in arrhythmogenic cardiomyopathy. Circulation 2015; 131:2233–5. DOI: 10.1161/CIRCULATIONAHA.115.014371
Jain R, Dalal D, Daly A, Tichnell C, et al. Electrocardiographic features of arrhythmogenic right ventricular dysplasia. Circulation 2009; 120:477. DOI: 10.1161/CIRCULATIONAHA.108.838821
Andreu D, Fernández –Armenta J, Acosta J, et al. A QRS axis-based algorithm to identify the origin of scar –related ventricular taqhycardia in the 17- segment American Heart Association model. Heart Rhythm.2018;15(10): 1491-1497. DOI: 10.1016/j.hrthm.2018.06.013
Corrado D, Basso C, Judge D. Arrhythmogenic cardiomyopathy. Circ Res 2017; 121:784–802. DOI: 10.1161/CIRCRESAHA.117.309345
Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation 2006;113:1634–1637. DOI: 10.1161/CIRCULATIONAHA.105.616490
Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115:1710–1720. DOI: 10.1161/CIRCULATIONAHA.106.660241
Sen-Chowdhry S, Syrris P, Prasad S, et al. Left-dominant arrhythmogenic cardiomyopathy: an underrecognized clinical entity. J Am Coll Cardiol 2008;52:2175–2187. DOI: 10.1016/j.jacc.2008.09.019
Basso C, Thiene G. Adipositas cordis, fatty infiltration of the right ventricle, and arrhythmogenic right ventricular cardiomyopathy. Just a matter of fat? Cardiovascular Pathology 14 (2005) 37 – 41. DOI: 10.1016/j.carpath.2004.12.001
Basso C, Ronco F, Marcus F, et al. Quantitative assessment of endomyocardial biopsy in arrhythmogewe3nic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. Eur Heart J 2008;29:2760–2771. DOI: 10.1093/eurheartj/ehn415
Te Riele A, Tandri H, Bluemke D. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson 2014;16:50. DOI: https://doi.org/10.1186/s12968-014-0050-8
Perazzolo M, Rizzo S, Bauce B, et al. Arrhythmogenic right ventricular cardiomyopathy. Contribution of cardiac magnetic resonance imaging to the diagnosis. Herz 2015; 40:600–606. DOI: 10.1007/s00059-015-4228-0
Marcus FI, McKenna WJ, Sherrill D, Basso C, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121:1533–1541. DOI: 10.1161/CIRCULATIONAHA.108.840827
Aquaro GD, Barison A, Todiere G, et al. Usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2016;118:1730–1736. DOI: 10.1016/j.amjcard.2016.08.056
Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. J Am Coll Cardiol 2010;56:1864–94. DOI: 10.1016/j.jacc.2010.07.005
Te Riele AS, Tandri H, Sanborn DM, Bluemke DA. Noninvasive multimodality imaging in ARVD/C. J Am Coll Cardiol Img 2015;8:597–611. DOI: 10.1016/j.jcmg.2015.02.007
Kimura F, Sakai F, Sakomura Y, et al. Helical CT features of arrhythmogenic right ventricular cardiomyopathy. RadioGraphics 2002;22:1111–24. DOI: 10.1148/radiographics.22.5.g02se031111
Calkins H, Corrado D, Marcus F. Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2017;136: 2068–2082. DOI: 10.1161/CIRCULATIONAHA.117.030792
Li K, Bazoukis G, Liu T et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in clinical practice. Journal of Arrhythmia. 2018; 34:11–22. DOI: 10.1002/joa3.12021
Donato G, De Luca A, Cappelletto C, et al. Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. J Am Coll Cardiol 2020; 75:2753–65. DOI: 10.1016/j.jacc.2020.04.023
Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010;122: 1144–52. DOI: 10.1161/CIRCULATIONAHA.109.913871
Bhonsale A, Groeneweg J, James C, et al. Impact of genotype on clinical course in arrhythmogenic riight ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 2015; 36:847–55. DOI: 10.1093/eurheartj/ehu509
Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013;6: 533–42. DOI: https://doi.org/10.1161/CIRCGENETICS.113.000288
Elliott P, Anastasakis A, Asimaki A, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European journal of heart failure 2019; 21(8): 955–64. DOI: https://doi.org/10.1002/ejhf.1534
Published
Issue
Section
